Prediction of broad spectrum resistance of tumors towards anticancer drugs

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2405-2412

  Efferth, Thomas ^a,e   Konkimalla, V Badireenath ^a   Wang, Yi Fen ^b   Sauerbrey, Axel ^c   Meinhardt, Silke ^d   Zintl, Felix ^d   Mattern, Jürgen ^a   Volm, Manfred ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; EPIRUBICINOL; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IDARUBICINOL; METHOTREXATE; MITOPODOZIDE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; PROCARBAZINE; TRIAZIQUONE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ARTICLE; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; P-GLYCOPROTEIN;

EID: 42249087303     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4525     Document Type: Article

References (33)

1. Rhoads CP. Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease. Trans Assoc Am Physicians 1947;60:110-7.
2. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999;17:1625-31.
3. Salmon SE, Hamburger AW, Soehnlein B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-7.
4. Volm M, Kaufmann M, Hinderer H, Goerttler K. Rapid method for sensitivity testing of tumors against cytostatic agents. Klin Wochenschr 1970;48:374-6.
5. Volm M, Wayss K, Kaufmann M, Mattern J. Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 1979;15:983-93.
6. Volm M, Drings P, Hahn EW, Mattern J. Prediction of the clinical chemotherapeutic response of the stage III lung adenocarcinoma patients by an in vitro short term test. Br J Cancer 1988;57:198-200.
7. Group of Sensitivity Testing of Tumors (KSST): in vitro short term test to determine the resistance of human tumours to chemotherapy. Cancer 1981;48:2127-35.
8. Kimmig A, Gekeler V, Neumann M, et al. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 1990;50:6793 -9.
9. Gillet JP, Efferth T, Steinbach D, et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004;64:8987-93.
10. Wang YF, Cao JX, Efferth T, Lai GF, Luo SD. Cytotoxic and new tetralone derivatives from Berchemia floribunda (Wall.) Brongn. Chem Biodivers 2006;3:646-53.
11. Wang YF, Lai GF, Efferth T, Cao JX, Luo SD. New glycosides from Tetracentron sinense and their cytotoxic activity. Chem Biodivers 2006;3:1023-30.
12. Kaspers GJ, Pieters R, van Zantwijk CH, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991;64:469-74.
13. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
14. Alley MC, Scuderio DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
15. Wosikowski K, Schuurhuis D, Johnson K, et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997;89:1505 -15.
16. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
17. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
18. Konkimalla VB, Efferth T. Anti-cancer natural product library from traditional Chinese medicine. Comb Chem High Throughput Screen 2008;11:7-15.
19. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 2001;1:45-65.
20. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochem Biophys Acta Rev Cancer 2007;1775:237-62.
21. Volm M, Koomägi R, Efferth T. Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics 2004;1:157-66.
22. Efferth T, Volm M. Pharmacogenetics and individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-76.
23. Nobilit S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79.
24. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006;12:273-86.
25. Bickenbach K, Wilcox R, Veerapong J, et al. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg 2007;11:758-66.
26. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007;44:S15-24.
27. Wink M, Plant breeding: Importance of plant secondary metabolites for protection against pathogens and herbivores. Theor Appl Genet 1988;75:225-233.
28. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
29. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
30. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int JOncol 2001;18:767-73.
31. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002;28:160-8.
32. Adams M, Mahringer A, Bauer R, Fricker G, Efferth T. In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from Tetradium daniellii. Planta Med 2007;73:1475-8.
33. Adams M, Mahringer A, Kunert O, Fricker G, Efferth T, Bauer R. Cytotoxicity and P-glycoprotein modulating effects of quinolones and indoquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med 2007;73:1554-7.